The UK manufacturers of
cilostazol advise caution when it is given with drugs that are substrates of CYP3A4, especially those with a narrow therapeutic index. They specifically mention
nifedipine and
verapamil.
Monitor the outcome of concurrent use for an increase in the effects of
verapamil or
nifedipine (e.g. hypotension or bradycardia).